Stockreport

Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]

Phathom Pharmaceuticals, Inc.  (PHAT) 
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am Check Earnings Report
PDF Phathom Pharmaceuticals raised its full-year 2025 revenue guidance from $165-$175 million to $170-$175 million. The main reason why vonoprazan franchise sales grew by [Read more]